Submission declined on 6 July 2025 by Qcne (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: "[URL of reliable source]" is not a valid source?? -- NotCharizard 🗨 04:57, 4 July 2025 (UTC)
 |
Ansuman Satpathy (born c. 1983) is an American-Indian physician-scientist, immunologist, and venture capitalist. He is an Associate Professor of Pathology and Immunology at Stanford University School of Medicine, where he directs the Stanford Center for Immunotherapy Design. Satpathy is known for his work in cancer immunotherapy, single-cell genomics, and novel genomic technologies to study the immune system.[1] He is a co-founder of biotechnology companies, including Immunai, Cartography Biosciences, Santa Ana Bio, and Prox Biosciences, and a venture partner at Wing Venture Capital.[2]
Early Life and Education
[edit]Satpathy was born in Stuttgart, Germany.[3] He earned a Bachelor of Arts in Philosophy and a Bachelor of Science in Molecular Biology from the University of Illinois at Urbana-Champaign in 2006.[4] He completed an MD-PhD program at Washington University in St. Louis, earning his PhD in immunology in 2014 under Kenneth M. Murphy, studying dendritic cell biology.[5] Satpathy completed a residency in pathology and postdoctoral training in genetics at Stanford University under Howard Chang, joining the faculty in 2019.[6]
Career
[edit]Academic Research
[edit]At Stanford, Satpathy leads the Satpathy Lab, focusing on cancer immunology and immunogenomics.[7] His research uses single-cell sequencing and computational biology to study immune responses in cancer and infection.[8] Notable contributions include methods like single-cell RNA sequencing and ATAC-seq to profile immune cell states.[9] His work has been cited over 25,000 times.[10]
Satpathy co-directs the Parker Institute for Cancer Immunotherapy and the Immunotherapy Program at the Stanford Cancer Institute.[11] He is an affiliate investigator at the Gladstone-UCSF Institute of Genomic Immunology and a faculty fellow in Stanford’s ChEM-H program.[12]
Biotechnology and Venture Capital
[edit]Satpathy has co-founded several biotechnology companies, collectively raising over 1 billion dollars in venture capital funding:
- Immunai (2018), an AI-driven immune system mapping platform.[13]
- Cartography Biosciences (2021), focusing on precision oncology and T cell engager immunotherapies.[14]
- Santa Ana Bio (2023), targeting autoimmune diseases.[15]
- Arpelos Biosciences (2024), developing proximity-based therapeutics.[16]
Since 2023, he has been a venture partner at Wing Venture Capital, investing in biotechnology and health technology companies.[17]
Selected Publications
[edit]- McGinnis, C. S., et al. (2024). “The temporal progression of lung immune remodeling during breast cancer metastasis.” Cancer Cell.[18]
- Abay, T., et al. (2025). “Transcript-specific enrichment enables profiling of rare cell states via single-cell RNA sequencing.” Nature Genetics.[19]
References
[edit]- ^ Stanford Profiles: Ansuman Satpathy
- ^ Wing Venture Capital: Ansuman Satpathy
- ^ [URL of source confirming birth, if available]
- ^ Stanford Profiles
- ^ Washington University MSTP
- ^ Stanford Profiles
- ^ Satpathy Lab
- ^ Google Scholar: Ansuman Satpathy
- ^ [URL of Nature or Immunity publication]
- ^ Google Scholar
- ^ Parker Institute
- ^ Gladstone Institutes
- ^ [URL of reliable source]
- ^ [URL of reliable source]
- ^ [URL of reliable source]
- ^ [URL of reliable source]
- ^ Wing Venture Capital
- ^ [DOI or URL]
- ^ [DOI or URL]
- Promotional tone, editorializing and other words to watch
- Vague, generic, and speculative statements extrapolated from similar subjects
- Essay-like writing
- Hallucinations (plausible-sounding, but false information) and non-existent references
- Close paraphrasing
Please address these issues. The best way to do it is usually to read reliable sources and summarize them, instead of using a large language model. See our help page on large language models.